Bn-N(EtO2H)Gly-His(1-Trt)-OMe | 1333226-97-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: Bn-N(EtO2H)Gly-His(1-Trt)-OMe
• 英文别名: 2-[benzyl-[2-[[(2S)-1-methoxy-1-oxo-3-(1-tritylimidazol-4-yl)propan-2-yl]amino]-2-oxoethyl]amino]acetic acid
• CAS: 1333226-97-3
• 化学式: C₃₇H₃₆N₄O₅
• 分子量: 616.717
• InChiKey: LWSJDCNJAORMKY-XIFFEERXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  46
• 可旋转键数：
  15
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Bn-N(EtO2H)Gly-His(1-Trt)-OMe 在 三异丙基硅烷 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 (benzyl-{[(S)-2-(1H-imidazol-4-yl)-1-methylcarbamoyl-ethylcarbamoyl]-methyl}-amino)-acetic acid. 2TFA
  参考文献：
  名称：

  Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis

  摘要：

  Insulin degrading enzyme (IDE) is a highly conserved zinc metalloprotease that is involved in the clearance of various physiologically peptides like amyloid-beta and insulin. This enzyme has been involved in the physiopathology of diabetes and Alzheimer's disease. We describe here a series of small molecules discovered by screening. Co-crystallization of the compounds with IDE revealed a binding both at the permanent exosite and at the discontinuous, conformational catalytic site. Preliminary structure activity relationships are described. Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible. Neuroblastoma cells treated with the optimized compound display a dose-dependent increase in amyloid-beta levels. (c) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.04.009
• 作为产物：
  描述：

  溴甲苯 在 乙酸酐 、 N,N-二异丙基乙胺 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 生成 Bn-N(EtO2H)Gly-His(1-Trt)-OMe
  参考文献：
  名称：

  Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis

  摘要：

  Insulin degrading enzyme (IDE) is a highly conserved zinc metalloprotease that is involved in the clearance of various physiologically peptides like amyloid-beta and insulin. This enzyme has been involved in the physiopathology of diabetes and Alzheimer's disease. We describe here a series of small molecules discovered by screening. Co-crystallization of the compounds with IDE revealed a binding both at the permanent exosite and at the discontinuous, conformational catalytic site. Preliminary structure activity relationships are described. Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible. Neuroblastoma cells treated with the optimized compound display a dose-dependent increase in amyloid-beta levels. (c) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.04.009

文献信息

• Ligands of insulin degrading enzyme and their uses
  申请人：Université de Lille 2 Droit et Santé

  公开号：EP2371421A1

  公开（公告）日：2011-10-05

  The invention relates to ligands of insulin degrading enzyme and to their uses. The ligands of the invention are non peptidic and bind specifically to the exosite of insulin degrading enzyme. They are useful, in particular a use in the pharmaceutical field.

  该发明涉及胰岛素降解酶的配体及其用途。该发明的配体为非肽类，并特异性结合到胰岛素降解酶的外位点。它们在药物领域中特别有用。